Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes.

ABSTRACT:

Background

The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients' health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients' HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS.

Methods

In this cross-sectional, qualitative study, 16 patients aged ≥18 years with lower-risk MDS, who were RBC transfusion dependent, literate an

SUBMITTER: Trudeau JJ 

PROVIDER: S-EPMC7450032 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature